Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer

Author： Genova Carlo Rijavec Erika Barletta Giulia Sini Claudio Dal Bello Maria Giovanna Truini Mauro Murolo Carmelina Pronzato Paolo Grossi Francesco

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.12, Iss.7, 2012-07, pp. : 939-948

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management

By Movva Sujana Verschraegen Claire

Expert Opinion on Biological Therapy, Vol. 9, Iss. 2, 2009-02 ,pp. : 231-241

Informa Healthcare

Access to resources Recommend Favorite

The role of talactoferrin alfa in the treatment of non-small cell lung cancer

By Kelly Ronan J Giaccone Giuseppe

Expert Opinion on Biological Therapy, Vol. 10, Iss. 9, 2010-09 ,pp. : 1379-1386

Informa Healthcare

Access to resources Recommend Favorite

The development of immunotherapies for non-small cell lung cancer

By Salgaller Michael L

Expert Opinion on Biological Therapy, Vol. 2, Iss. 3, 2002-03 ,pp. : 265-278

Informa Healthcare

Access to resources Recommend Favorite

Cetuximab in non-small cell lung cancer

By Ademuyiwa Foluso O Hanna Nasser

Expert Opinion on Biological Therapy, Vol. 8, Iss. 1, 2008-01 ,pp. : 107-113

Informa Healthcare

Access to resources Recommend Favorite

Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development

By Dienstmann Rodrigo Felip Enriqueta

Expert Opinion on Biological Therapy, Vol. 11, Iss. 9, 2011-09 ,pp. : 1223-1231

Informa Healthcare

Access to resources Recommend Favorite